Trial Profile
A multicentre phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Tavokinogene telseplasmid (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors OncoSec Medical
- 17 Mar 2020 Results presented in the OncoSec Medical Media Release.
- 01 Feb 2020 Results assessing efficacy and safety of tavokinogene telseplasmid in malignant melanoma patients, published in the Annals of Oncology.
- 29 Nov 2018 Results presented in an OncoSec Medical Media Release.